Sermorelin 5mg

Sermorelin is a synthetic peptide identical to the first 29 amino acids of human growth-hormone-releasing hormone (GHRH). The full endogenous GHRH is 44 residues, but biochemistry work in the 1980s established that the N-terminal 29 amino acids retain essentially full receptor-binding and growth-hormone-releasing activity, which made the 1–29 fragment a more practical research and clinical tool than the longer parent peptide. Sermorelin is the unmodified GHRH(1-29) sequence; this guide explains what it is, how it sits in the family of GHRH analogues, and how its quality is independently verified.

Sermorelin has the sequence Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 — 29 residues with a C-terminal amide. The molecular weight is approximately 3358 g/mol. Unlike its stabilized analogue CJC-1295 No-DAC (which carries four substitutions for protease resistance), Sermorelin is the native unmodified sequence and is consequently more susceptible to enzymatic cleavage in physiological conditions. It is supplied as a lyophilized white powder for laboratory reconstitution.

Sermorelin is sold strictly for laboratory and research use. It is not approved by the FDA in its current research-grade form for human or veterinary use, and nothing in this guide constitutes guidance for human administration. A pharmaceutical preparation of sermorelin acetate historically had FDA approval but was withdrawn from market by the original manufacturer; that is a separate regulatory history from the research-grade lyophilized peptide supplied here.

Published research on Sermorelin centers on GHRH-receptor pharmacology and the upstream regulation of growth-hormone pulsatility. Because Sermorelin is the unmodified GHRH(1-29) sequence, it is often used as the reference compound in studies that compare modified GHRH analogues (CJC-1295 No-DAC, CJC-1295 With-DAC, Tesamorelin) against the native sequence. Researchers studying the GHRH axis directly — rather than studying the practical effects of half-life extension — frequently choose Sermorelin specifically for this reason. The shorter half-life is a feature, not a limitation, when the research question requires a pulse-like exposure profile.

Every batch of MHS Longevity Sermorelin is submitted to an independent third-party laboratory before release:

Lyophilized Sermorelin should be stored at -20°C or below for extended stability. Once reconstituted in bacteriostatic water, the solution is typically held at 2–8°C and used within the documented stability window. Native (unmodified) GHRH sequences are more susceptible to enzymatic degradation than the stabilized analogues — researchers using Sermorelin in protocols that require longer in-solution stability should be aware of this and aliquot accordingly. Repeated freeze–thaw cycles should be avoided. Standard aseptic technique applies during reconstitution.